Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
Pierre Fabre Medicament Identifier:
First received: February 3, 2010
Last updated: October 12, 2016
Last verified: October 2016
In metastatic breast cancer (MBC) patients who have already received anthracyclines, taxanes, antimetabolites and vinca-alkaloids and have developed drug resistance to these drugs, therapeutic options are very limited. Alkylating agents showed a modest activity in pretreated metastatic breast cancer. This phase III trial will compare the effectiveness and the safety profile of vinflunine to an alkylating agent of physician choice in MBC patients who have exhausted anthracyclines, taxanes, antimetabolites and vinca-alkaloids.

Condition Intervention Phase
Breast Cancer
Drug: vinflunine
Drug: alkylating agent of physician choice registered in cancer
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Pierre Fabre Medicament:

Primary Outcome Measures:
  • Overall survival [ Time Frame: monthly for 6 months after disease progression and then every 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Quality of life questionnaire [ Time Frame: every 6 weeks ] [ Designated as safety issue: No ]
  • Adverse event profile [ Time Frame: monthly ] [ Designated as safety issue: Yes ]
  • Tumour response rate [ Time Frame: every 6 weeks until disease progression ] [ Designated as safety issue: No ]
  • Progression free survival [ Time Frame: every 6 weeks until disease progression ] [ Designated as safety issue: No ]

Enrollment: 594
Study Start Date: September 2009
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: arm A: Vinflunine
Drug: vinflunine
280 mg/m2 on day 1 of each cycle every 3 weeks
Active Comparator: arm B: Alkylating agent of physician choice Drug: alkylating agent of physician choice registered in cancer
cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:(main conditions)

  • Female patients 18 to 75 years of age with metastatic breast cancer histologically/cytologically confirmed not amenable to curative surgery or radiotherapy and who have received at least two prior chemotherapy regimens including anthracyclines,taxanes,antimetabolite and vinca-alkaloid and are no longer candidate for these drugs,
  • Karnofsky performance score of at least 70 %, adequate haematological, hepatic and renal functions and ECG without clinically relevant abnormality.

Exclusion Criteria:

  • Concurrent serious uncontrolled medical disorder,
  • known or clinical evidence of brain metastases or leptomeningeal involvement,
  • pulmonary lymphangitis or symptomatic pleural effusion or symptomatic ascites,
  • history of second primary malignancy,
  • HIV infection, preexisting neuropathy,
  • pregnancy or breast feeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01091168

  Show 81 Study Locations
Sponsors and Collaborators
Pierre Fabre Medicament
  More Information

Responsible Party: Pierre Fabre Medicament Identifier: NCT01091168     History of Changes
Other Study ID Numbers: L00070 IN 308 B0 
Study First Received: February 3, 2010
Last Updated: October 12, 2016
Health Authority: Austria: Federal Office for Safety in Health Care
Russia: Ministry of Health of the Russian Federation
Germany: Federal Institute for Drugs and Medical Devices
Ukraine: State Pharmacological Center - Ministry of Health
Belarus: Ministry of Health
Taiwan: Department of Health
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
United Kingdom: Medicines and Healthcare Products Regulatory Agency
South Africa: Medicines Control Council
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
Portugal: National Authority for Drug and Health Products, I.P.
Spain: Agencia Espanõla de Medicamentos y Productos Sanitarios
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Switzerland: Swissmedic
Belgium: Federal Agency for Medicinal Products and Health Products

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Alkylating Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on December 06, 2016